Literature DB >> 7593903

Low blood flow extracorporeal carbon dioxide removal (ECCO2R): a review of the concept and a case report.

N M Habashi1, U R Borg, H N Reynolds.   

Abstract

Despite advances in respiratory and critical care medicine, the mortality from ARDS remains unchanged. Recent research suggests current ventilatory therapy may produce additional lung injury, retarding the recovery process of the lung. Alternative supportive therapies, such as ECMO and ECCO2R, ultimately may result in less ventilator induced lung injury. Due to the invasiveness of ECMO/ECCO2R, these modalities are initiated reluctantly and commonly not until patients suffer from terminal or near-terminal respiratory failure. Low flow ECCO2R may offer advantages of less invasiveness and be suitable for early institution before ARDS becomes irreversible. We describe a patient with ARDS and severe macroscopic barotrauma supported with low flow ECCO2R resulting in significant CO2 clearance, reduction of peak, mean airway pressures and minute ventilation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7593903     DOI: 10.1007/BF01700166

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  30 in total

1.  Prognosis after recovery from adult respiratory distress syndrome.

Authors:  S Lakshminarayan; R E Stanford; T L Petty
Journal:  Am Rev Respir Dis       Date:  1976-01

Review 2.  Adult respiratory-distress syndrome: changing concepts of lung injury and repair.

Authors:  J E Rinaldo; R M Rogers
Journal:  N Engl J Med       Date:  1982-04-15       Impact factor: 91.245

3.  Adult respiratory distress syndrome. Prognosis after onset.

Authors:  A A Fowler; R F Hamman; G O Zerbe; K N Benson; T M Hyers
Journal:  Am Rev Respir Dis       Date:  1985-09

4.  High inflation pressure pulmonary edema. Respective effects of high airway pressure, high tidal volume, and positive end-expiratory pressure.

Authors:  D Dreyfuss; P Soler; G Basset; G Saumon
Journal:  Am Rev Respir Dis       Date:  1988-05

5.  Randomized clinical trial of pressure-controlled inverse ratio ventilation and extracorporeal CO2 removal for adult respiratory distress syndrome.

Authors:  A H Morris; C J Wallace; R L Menlove; T P Clemmer; J F Orme; L K Weaver; N C Dean; F Thomas; T D East; N L Pace; M R Suchyta; E Beck; M Bombino; D F Sittig; S Böhm; B Hoffmann; H Becks; S Butler; J Pearl; B Rasmusson
Journal:  Am J Respir Crit Care Med       Date:  1994-02       Impact factor: 21.405

6.  Pulmonary function after recovery from the adult respiratory distress syndrome.

Authors:  J J Klein; J R van Haeringen; H J Sluiter; R Holloway; R Peset
Journal:  Chest       Date:  1976-03       Impact factor: 9.410

7.  Intermittent positive-pressure hyperventilation with high inflation pressures produces pulmonary microvascular injury in rats.

Authors:  D Dreyfuss; G Basset; P Soler; G Saumon
Journal:  Am Rev Respir Dis       Date:  1985-10

8.  Pressure-volume curve of total respiratory system in acute respiratory failure. Computed tomographic scan study.

Authors:  L Gattinoni; A Pesenti; L Avalli; F Rossi; M Bombino
Journal:  Am Rev Respir Dis       Date:  1987-09

9.  Digital computer procedure for the conversion of PCO2 into blood CO2 content.

Authors:  G R Kelman
Journal:  Respir Physiol       Date:  1967-08

10.  Causes of mortality in patients with the adult respiratory distress syndrome.

Authors:  A B Montgomery; M A Stager; C J Carrico; L D Hudson
Journal:  Am Rev Respir Dis       Date:  1985-09
View more
  2 in total

1.  What's new in extracorporeal carbon dioxide removal for COPD?

Authors:  Darryl Abrams; Roberto Roncon-Albuquerque; Daniel Brodie
Journal:  Intensive Care Med       Date:  2015-02-03       Impact factor: 17.440

2.  Effect of impeller design and spacing on gas exchange in a percutaneous respiratory assist catheter.

Authors:  R Garrett Jeffries; Brian J Frankowski; Greg W Burgreen; William J Federspiel
Journal:  Artif Organs       Date:  2014-04-22       Impact factor: 3.094

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.